Whetstone Capital Advisors LLC Buys Shares of 8,745 Kenvue Inc. (NYSE:KVUE)

Whetstone Capital Advisors LLC bought a new position in Kenvue Inc. (NYSE:KVUE) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 8,745 shares of the company’s stock, valued at approximately $202,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Riverview Trust Co purchased a new stake in shares of Kenvue during the third quarter worth $30,000. Ashton Thomas Securities LLC acquired a new position in Kenvue in the third quarter worth approximately $35,000. Studio Investment Management LLC raised its holdings in shares of Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after purchasing an additional 845 shares in the last quarter. Deseret Mutual Benefit Administrators boosted its stake in shares of Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after acquiring an additional 651 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in shares of Kenvue during the 2nd quarter worth $61,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.1 %

Shares of KVUE opened at $24.11 on Monday. The stock’s fifty day simple moving average is $22.84 and its 200-day simple moving average is $20.87. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $46.23 billion, a PE ratio of 43.78, a price-to-earnings-growth ratio of 2.19 and a beta of 1.36. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.31.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter last year, the firm earned $0.31 EPS. As a group, research analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.40%. Kenvue’s dividend payout ratio is presently 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several analyst reports. Jefferies Financial Group started coverage on Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective on the stock. Bank of America upped their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a report on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft boosted their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Piper Sandler raised their price target on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.